These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 25466361)

  • 1. The clinical significance of persistent cancer cells on prostate biopsy after high-dose-rate brachytherapy boost for intermediate-risk prostate cancer.
    D'Alimonte L; Helou J; Sherman C; Loblaw A; Chung HT; Ravi A; Deabreu A; Zhang L; Morton G
    Brachytherapy; 2015; 14(3):309-14. PubMed ID: 25466361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients.
    Joseph N; Taylor C; O'Hara C; Choudhury A; Elliott T; Logue J; Wylie J
    Radiother Oncol; 2016 Nov; 121(2):299-303. PubMed ID: 28029404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose-rate brachytherapy boost for intermediate risk prostate cancer: Long-term outcomes of two different treatment schedules and early biochemical predictors of success.
    Helou J; D'Alimonte L; Loblaw A; Chung H; Cheung P; Szumacher E; Danjoux C; Ravi A; Deabreu A; Zhang L; Morton G
    Radiother Oncol; 2015 Apr; 115(1):84-9. PubMed ID: 25770875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radical dose escalation by high-dose-rate brachytherapy for localized prostate cancer-Significance of prostate-specific antigen nadir level within 18 months as correlation for long-term biochemical control.
    Schroeder C; Geiger F; Siebert FA; Baumann R; Bockelmann G; Schultze J; Kimmig B; Dunst J; Galalae R
    Brachytherapy; 2019; 18(1):8-12. PubMed ID: 30482622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy.
    Kestin LL; Goldstein NS; Vicini FA; Martinez AA
    J Urol; 2002 Nov; 168(5):1994-9. PubMed ID: 12394693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma.
    Ellis RJ; Vertocnik A; Kim E; Zhou H; Young B; Sodee B; Fu P; Beddar S; Colussi V; Spirnak JP; Dinchman KH; Resnick M; Kinsella TJ
    Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):362-70. PubMed ID: 12957246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
    Ko EC; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Four-year outcomes of hypofractionated high-dose-rate prostate brachytherapy and external beam radiotherapy.
    Chen WC; Tokita KM; Ravera J; Fu P; Jiang Y; Kaminsky DA; Ponsky L; Ellis RJ
    Brachytherapy; 2013; 12(5):422-7. PubMed ID: 23380382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathologic evidence of dose-response and dose-volume relationships for prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy.
    Kestin LL; Goldstein NS; Vicini FA; Mitchell C; Gustafson GS; Stromberg JS; Chen PY; Martinez AA
    Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):107-18. PubMed ID: 12182980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results of a prospective, Phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer.
    Dibiase SJ; Hussain A; Kataria R; Amin P; Bassi S; Dawson N; Kwok Y
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):732-6. PubMed ID: 21036486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An eight-year experience of HDR brachytherapy boost for localized prostate cancer: biopsy and PSA outcome.
    Bachand F; Martin AG; Beaulieu L; Harel F; Vigneault E
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):679-84. PubMed ID: 18963537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
    Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
    Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer.
    Patel S; Demanes DJ; Ragab O; Zhang M; Veruttipong D; Nguyen K; Park SJ; Marks L; Pantuck A; Steinberg M; Kamrava M
    Brachytherapy; 2017; 16(2):299-305. PubMed ID: 27965117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favorable Preliminary Outcomes for Men With Low- and Intermediate-risk Prostate Cancer Treated With 19-Gy Single-fraction High-dose-rate Brachytherapy.
    Krauss DJ; Ye H; Martinez AA; Mitchell B; Sebastian E; Limbacher A; Gustafson GS
    Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):98-106. PubMed ID: 27979460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer.
    Anwar M; Weinberg V; Seymour Z; Hsu IJ; Roach M; Gottschalk AR
    Radiat Oncol; 2016 Jan; 11():8. PubMed ID: 26792201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between biochemical failure and time to nadir in patients treated with external beam therapy for T1-T3 prostate carcinoma.
    Aref I; Eapen L; Agboola O; Cross P
    Radiother Oncol; 1998 Aug; 48(2):203-7. PubMed ID: 9783893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancer.
    Agarwal M; Chhabra AM; Amin N; Braccioforte MH; Molitoris JK; Moran BJ
    Brachytherapy; 2018; 17(6):882-887. PubMed ID: 30143400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
    Urology; 2004 Oct; 64(4):754-9. PubMed ID: 15491715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.